is semaglutide for diabetes (Ozempic/Wegovy) shows 3-year efficacy blood sugar control and weight loss Peptide of the Week: Semaglutide

Current regulatory stance: The FDA has not publicly addressed retatrutide compounding

[4] In the SURMOUNT-1 obesity trial, a 72-week placebo-controlled study in 2,539 adults with obesity (without diabetes), mean weight change was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses versus 3.1% for placebo

Beginning a GLP-1 often brings changes that extend beyond cravings or appetite

Persistent vomiting or diarrhea : Seek urgent care if unable to maintain hydration or if severe gastrointestinal symptoms persist for more than 24 hours

Animal studies show BPC-157 accelerates tendon-to-bone healing, improves collagen organization, and reduces inflammatory markers in tendon tissue